HealthMap

MTHFR C677T and Folate Conversion

• Yes, the MTHFR C677T genetic variant significantly impairs the body's ability to convert dietary folate and synthetic folic acid into its active, usable form.
• The MTHFR enzyme (methylenetetrahydrofolate reductase) is responsible for converting 5,10-methylenetetrahydrofolate into 5-methyltetrahydrofolate (5-MTHF), which is the primary circulating form of folate in the blood.
• When an individual carries the C677T variant, the efficiency of this enzyme is reduced:
• Heterozygous individuals (one copy of the variant) typically retain about 60-70% of normal enzyme function.
• Homozygous individuals (two copies of the variant) may experience a reduction in enzyme activity down to 30-40% of normal levels.
• This impairment leads to a decreased production of 5-MTHF, which can negatively impact key biochemical pathways, most notably the methylation cycle and the conversion of homocysteine to methionine.
• Consequently, individuals with this variant often benefit from bypassing the enzymatic bottleneck by consuming pre-methylated folate (such as L-methylfolate) rather than standard folic acid.